Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · May 30, 2019

Early Intensive Disease- Modifying Therapy Is Superior to Escalation Therapy for Multiple Sclerosis

JAMA Neurology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Neurology
Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in Patients With Multiple Sclerosis
JAMA Neurol 2019 Feb 18;[EPub Ahead of Print], K Harding, O Williams, M Willis, J Hrastelj, A Rimmer, F Joseph, V Tomassini, M Wardle, T Pickersgill, N Robertson, E Tallantyre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading